The Ulcerative Colitis Game Of Thrones

Cureveda Gets NIH SBIR Grant to Develop a Novel Treatment for Ulcerative Colitis

The differences don't stop there. Xeljanz operates within cells to inhibit the function of cytokines -- molecules with functions similar to hormones -- like tumor necrosis factor (TNF). Remicade, Simponi, and Humira work outside of cells by binding to TNF and limiting its function. The FDA has already approved Xeljanz for treatment of rheumatoid arthritis in the U.S., but the drug isn't having the same luck in Europe. Last month, The Committee for Medicinal Products for Human Use advised the European Medicines Agency not to approve Xeljanz. The advisory board claims that the treatment isn't effective enough and therefore shouldn't be approved. Some Room at the Top for Everyone When the FDA announced its approval of Humira for treatment of ulcerative colitis, Division of Gastroenterology and Inborn Errors Products Director Donna Griebel, M.D., stated that "each patient with ulcerative colitis experiences the disease differently, and treatment must be adjusted to meet each individual's needs." Since different patients respond to different treatments, it is unlikely that any single drug will completely dominate the growing ulcerative colitis market. Q1 2013 Sales Oral No The estimated 700,000 Americans, and millions worldwide, suffering from ulcerative colitis will most likely have several options to treat the affliction. Assuming Pfizer's Xeljanz is approved for ulcerative colitis, patients will soon have the option of a pill, subcutaneous injection, and/or IV treatments. It looks like the battle for the top spot will be exciting and unpredictable for years to come. Source: The Ulcerative Colitis Game Of Thrones Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. see it here

Story continues below In a release, the Company said that it will use the funds to further research on a novel small molecule Nrf2 activator called VEDA-1209. In collaboration with scientists at Johns Hopkins University, Temple University and Georgia State University, Cureveda will first examine the pharmacokinetic and pharmacodynamics of VEDA-1209 when administered to mice. The results generated will form the basis for selecting a dosing regimen to test VEDA-1209's efficacy in an animal model of ulcerative colitis. If successful, this project will provide proof of concept supporting further development of VEDA-1209 towards clinical trials in colitis patients. Ulcerative colitis is a form of inflammatory bowel disease (IBD) and affects approximately 500,000 individuals in the United States each year. Cureveda said that current treatments focus mainly on symptom relief and there is a major unmet need for more effective therapies that can target the underlying disease process and prevent disease progression. Inflammation and cellular dysfunction due to oxidative stress appear to play a role in the etiology of ulcerative colitis. The current project is designed to test the hypothesis that a Nrf2 activator can stimulate antioxidant pathways and counteract disease progression in an animal model of ulcerative colitis. SBIR grants are funded by the federal government and awarded to companies with fewer than 500 employees to further their technological innovation and commercialization potential. Cureveda's award was granted by the National Institute of Diabetes and Digestive and Kidney Diseases for the amount of $150,000. "We are excited to receive this SBIR award which will help us advance our program to develop Nrf2 activators to treat ulcerative colitis," said Graham Allaway, Cureveda's COO. "This funding opportunity will also allow Cureveda to progress its studies of the role of oxidative stress in the etiology of inflammatory diseases." ((Comments on this story may be sent to more info here